Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157016 | 0.91 | CYP1A2 (0.38) | TAAR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15310108 | 0.88 | TAAR1 (0.39) | TAAR1P2RX7CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3415726 | 0.88 | TAAR1 (0.40) | TAAR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3670063 | 0.86 | TAAR1 (0.36) | TAAR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12637716 | 0.85 | TAAR1 (0.35) | TAAR1P2RX7ADRA2AADRA1ACFB | |
| SCHEMBL3804757 | 0.85 | CFB (0.36) | TAAR1ADRA2AADRA1ACFB | |
| SCHEMBL1156800 | 0.83 | DRD2 (0.37) | P2RX7CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1157133 | 0.81 | CYP3A4 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1156686 | 0.80 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1157356 | 0.80 | TAAR1 (0.37) | TAAR1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251865-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3332782-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2017-03-23 | — | — | US | disclosed |
| US-9545394-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9545394-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9289420-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289420-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140066483-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066483-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8575207-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ALLERGAN, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2240468-B1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012024161-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120041031-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041031-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041031-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | TAAR1 267/4885P2RX7 291/4885CYP1A2 688/4885 |
| US-20180071259-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | TAAR1 263/4885P2RX7 305/4885CYP1A2 585/4885 |
| US-20140066483-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | TAAR1 267/4885P2RX7 291/4885CYP1A2 688/4885 |
| US-20160158199-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | TAAR1 263/4885P2RX7 305/4885CYP1A2 585/4885 |
| US-20170079956-A1 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS | ADRA2B, ADRB2, ADRA2A | TAAR1 280/4885P2RX7 301/4885CYP1A2 514/4885 |
| US-10251865-B2 | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists | ADRA2B, ADRB2, ADRA2A | TAAR1 263/4885P2RX7 305/4885CYP1A2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.